The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Serazide     2-amino-3-hydroxy-N'- [(2,3,4...

Synonyms: Benserazida, benserazide, Benseraszide, Benserazidum, AG-F-07705, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of benserazide


Psychiatry related information on benserazide


High impact information on benserazide

  • In a study of 3 patients in whom L-dopa/benserazide was started, plasma ALAAD rose gradually over 3 to 4 weeks [10].
  • The hyperinsulinaemic and hypoglycaemic actions of 5HTP in normal mice were prevented completely by pretreatment with benserazide, an inhibitor of aromatic amino acid decarboxylase [11].
  • Among the catechol drugs used in the L-DOPA treatment of Parkinson's disease, the COMT inhibitors entacapone and tolcapone were not methylated, whereas the DOPA decarboxylase inhibitor benserazide was 15 times more specific substrate than L-DOPA, the target of COMT inhibition [12].
  • A single morning dose of dual-release formulation was compared with a slow-release formulation of L-dopa plus benserazide in a randomized, double-blind, cross-over study in 16 fluctuating patients with PD [13].
  • RESULTS: Preservation of the hippocampal CA1 cells was found in the brains treated with 300 mg/kg DOPS plus benserazide (neuronal density, 125 +/- 24 cells per millimeter) compared with the vehicle-treated ones (49 +/- 11 cells per millimeter) (P < .01) [14].

Chemical compound and disease context of benserazide


Biological context of benserazide


Anatomical context of benserazide


Associations of benserazide with other chemical compounds


Gene context of benserazide

  • To minimize side-effects, peripheral decarboxylase inhibition was achieved with benserazide (Ro 4-4602.) PRL increased significantly (P less than 0.01) after benserazide alone in all subjects [33].
  • Benserazide administration had no effect of basal GH levels, but a significant increase of GH release (P less than 0.01) was noticed 30-120 min after the end of 1-5 HTP infusion in both men and women [33].
  • Tyrosine hydroxylase inhibitor (H44/68) blocked SG behaviors, but dopamine-beta-hydroxylase inhibitors (FLA 63 and U-14, 624) and combined administration of L-3,4-dihydroxyphenylalanine and Ro-4-4602 enhanced it [34].
  • This protective effect resulted from inhibition of TH and the consequent decrease in DA concentration, because treatment with L-DOPA/benserazide, which bypasses TH inhibition induced by alpha-MPT, reversed the protective effect produced by this drug [35].
  • Nine acromegalic patients and nine normal subjects were given a single 125 mg oral dose of benserazide, and serum GH, PRL, and TSH were determined by RIA methods every 30 min for 4 h [28].

Analytical, diagnostic and therapeutic context of benserazide

  • The patients were then given one tablet of Madopar((R)) (100 mg of L-dopa and 25 mg of benserazide), and the microdialysis was continued for another 210 min [36].
  • The aromatic amino acid decarboxylase inhibitor used was difluoromethyl-DOPA, which was shown to be more stable than NSD 1015 or Ro 4-4602 in the perfusion fluid [37].
  • 2. Studies were performed at 5-7 days post lesion (group 1 animals), at 21 days (group 2) when denervation supersensitivity was evident by contralateral turning to apomorphine and at the same time but following 7 days dosing with LDME plus benserazide (group 3) [38].
  • However, in benserazide- or L-dopa-treated animals, basal urine flow was not different from the control group [39].
  • After treatment with benserazide plus L-DOPA, an acute injection of L-DOPA evoked a release of dopamine which was twice as large in the as/agu rats compared with controls [40].


  1. Modulation of peroxidation in murine melanoma by dietary tyrosine-phenylalanine restriction, levodopa methylester chemotherapy, and sodium ascorbate supplementation. Pierson, H.F., Meadows, G.G. J. Natl. Cancer Inst. (1985) [Pubmed]
  2. Comparison of levodopa with carbidopa or benserazide in parkinsonism. Greenacre, J.K., Coxon, A., Petrie, A., Reid, J.L. Lancet (1976) [Pubmed]
  3. COMT inhibition: a new treatment strategy for Parkinson's disease. Kurth, M.C., Adler, C.H. Neurology (1998) [Pubmed]
  4. Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys. Grondin, R., Bédard, P.J., Hadj Tahar, A., Grégoire, L., Mori, A., Kase, H. Neurology (1999) [Pubmed]
  5. Clinical and cardiovascular effects of alpha methyldopa in combination with decarboxylase inhibitors. Kersting, F., Reid, J.L., Dollery, C.T. Clin. Pharmacol. Ther. (1977) [Pubmed]
  6. Effects of the nicotinic acetylcholine receptor agonist SIB-1508Y on object retrieval performance in MPTP-treated monkeys: comparison with levodopa treatment. Schneider, J.S., Van Velson, M., Menzaghi, F., Lloyd, G.K. Ann. Neurol. (1998) [Pubmed]
  7. Inhibition of brain dopa-decarboxylase by RO 4-4602 infused ICV blocks alcohol drinking induced in rats by cyanamide. Miñano, F.J., Myers, R.D. Psychopharmacology (Berl.) (1989) [Pubmed]
  8. L-hydroxytryptophan amplifies pulsatile secretion of LH in the follicular phase of normal women. Lado-Abeal, J., Rey, C., Cabezas-Agricola, J.M., Rodriguez, A., Camarero, E., Cabezas-Cerrato, J. Clin. Endocrinol. (Oxf) (1997) [Pubmed]
  9. Effect of serotoninergic drugs on positive and negative reinforcing systems in cats. Patkina, N.A., Lapin, I.P. Pharmacol. Biochem. Behav. (1976) [Pubmed]
  10. Induction of aromatic-L-amino acid decarboxylase by decarboxylase inhibitors in idiopathic parkinsonism. Boomsma, F., Meerwaldt, J.D., Man in 't Veld, A.J., Hovestadt, A., Schalekamp, M.A. Ann. Neurol. (1989) [Pubmed]
  11. Further studies on the effects of 5-hydroxytryptophan on plasma glucose and insulin in the mouse. Furman, B.L., Wilson, G.A. Diabetologia (1980) [Pubmed]
  12. Molecular mechanisms controlling the rate and specificity of catechol O-methylation by human soluble catechol O-methyltransferase. Lautala, P., Ulmanen, I., Taskinen, J. Mol. Pharmacol. (2001) [Pubmed]
  13. Dual-release formulation, a novel principle in L-dopa treatment of Parkinson's disease. Descombes, S., Bonnet, A.M., Gasser, U.E., Thalamas, C., Dingemanse, J., Arnulf, I., Bareille, M.P., Agid, Y., Rascol, O. Neurology (2001) [Pubmed]
  14. The protective effect of L-threo-3,4-dihydroxyphenylserine on ischemic hippocampal neuronal death in gerbils. Lee, T.H., Abe, K., Aoki, M., Nakamura, M., Kogure, K., Itoyama, Y. Stroke (1994) [Pubmed]
  15. Comparative effectiveness of two extracerebral DOPA decarboxylase inhibitors in Parkinson disease. Lieberman, A., Estey, E., Gopinathan, G., Ohashi, T., Sauter, A., Goldstein, M. Neurology (1978) [Pubmed]
  16. Bromocriptine alone or associated with L-dopa plus benserazide in Parkinson's disease. Caraceni, T.A., Celano, I., Parati, E., Girotti, F. J. Neurol. Neurosurg. Psychiatr. (1977) [Pubmed]
  17. Prevention of levodopa-induced dyskinesias by a selective NR1A/2B N-methyl-D-aspartate receptor antagonist in parkinsonian monkeys: implication of preproenkephalin. Morissette, M., Dridi, M., Calon, F., Tahar, A.H., Meltzer, L.T., Bédard, P.J., Di Paolo, T. Mov. Disord. (2006) [Pubmed]
  18. Prolactin response to acute administration of different L-dopa plus decarboxylase inhibitors in Parkinson's disease. Ruggieri, S., Falaschi, P., Baldassarre, M., D'Urso, R., De Giorgio, G., Rocco, A., Agnoli, A. Neuropsychobiology (1982) [Pubmed]
  19. Combined use of benserazide and carbidopa in Parkinson's disease. Lieberman, A.N., Goldstein, M., Gopinathan, G., Neophytides, A., Hiesiger, E., Walker, R., Nelson, J. Neurology (1984) [Pubmed]
  20. Uptake of L-3,4-dihydroxyphenylalanine and dopamine formation in cultured renal epithelial cells. Soares-da-Silva, P., Vieira-Coelho, M.A., Serrão, M.P. Biochem. Pharmacol. (1997) [Pubmed]
  21. Probenecid-induced increase of 5-hydroxytryptamine synthesis in rat brain, as measured by formation of 5-hydroxytryptophan. van Wijk, M., Sebens, J.B., Korf, J. Psychopharmacology (Berl.) (1979) [Pubmed]
  22. Substrate stereospecificity and selectivity of catechol-O-methyltransferase for DOPA, DOPA derivatives and alpha-substituted catecholamines. Gordonsmith, R.H., Raxworthy, M.J., Gulliver, P.A. Biochem. Pharmacol. (1982) [Pubmed]
  23. A pharmacokinetic model to predict the PK interaction of L-dopa and benserazide in rats. Grange, S., Holford, N.H., Guentert, T.W. Pharm. Res. (2001) [Pubmed]
  24. Serotonin agonists reduce dopamine synthesis in the striatum only when the impulse flow of nigro-striatal neurons is intact. Spampinato, U., Esposito, E., Samanin, R. J. Neurochem. (1985) [Pubmed]
  25. Differential effect of benserazide (Ro4-4602) on the concentration of indoleamines in rat pineal and hypothalamus. Arendt, J., Ho, A.K., Laud, C., Marston, A., Nohria, V., Smith, J.A., Symons, A.M. Br. J. Pharmacol. (1981) [Pubmed]
  26. Evidence for the involvement of P-glycoprotein on the extrusion of taken up L-DOPA in cyclosporine A treated LLC-PK1 cells. Soares-da-Silva, P., Serrão, M.P., Vieira-Coelho, M.A., Pestana, M. Br. J. Pharmacol. (1998) [Pubmed]
  27. Differential effect of benserazide on catecholamine concentrations in the rat pineal, cerebral cortex and hypothalamus. Ho, A.K., Smith, J.A. Biochem. Pharmacol. (1983) [Pubmed]
  28. Benserazide effects on growth hormone, prolactin, and thyrotropin in normal and acromegalic man. Masturzo, P., De Maria, A., Murialdo, G., Bonura, M.L., Zauli, C., Polleri, A. J. Clin. Endocrinol. Metab. (1985) [Pubmed]
  29. Cross talk between the intrarenal dopaminergic and cyclooxygenase-2 systems. Zhang, M.Z., Yao, B., McKanna, J.A., Harris, R.C. Am. J. Physiol. Renal Physiol. (2005) [Pubmed]
  30. Tryptophan pyrrolase in haem regulation. The mechanism of the opposite effects of tryptophan on rat liver 5-aminolaevulinate synthase activity and the haem saturation of tryptophan pyrrolase. Badawy, A.A., Welch, A.N., Morgan, C.J. Biochem. J. (1981) [Pubmed]
  31. Effects of levodopa alone and in combination with dopa-decarboxylase inhibitors on plasma renin activity in patients with Parkinson's disease. Rappelli, A., Glorioso, N., Tedde, R., Dessi'-Fulgheri, P., Monaco, F. J. Neurol. Neurosurg. Psychiatr. (1978) [Pubmed]
  32. Characteristics and specificity of phenelzine and benserazide as inhibitors of benzylamine oxidase and monoamine oxidase. Andree, T.H., Clarke, D.E. Biochem. Pharmacol. (1982) [Pubmed]
  33. Effect of 1-5 hydroxytryptophan infusion on growth hormone and prolactin secretion in man. Lancranjan, I., Wirz-Justice, A., Pühringer, W., Del Pozo, E. J. Clin. Endocrinol. Metab. (1977) [Pubmed]
  34. The involvement of serotonergic neurons in the central nervous system as the possible mechanism for slow head-shaking behavior induced by methamphetamine in rats. Honma, T., Fukushima, H. Psychopharmacology (Berl.) (1979) [Pubmed]
  35. Dopamine-dependent neurotoxicity of lipopolysaccharide in substantia nigra. De Pablos, R.M., Herrera, A.J., Villarán, R.F., Cano, J., Machado, A. FASEB J. (2005) [Pubmed]
  36. Human pharmacokinetics of L-3,4-dihydroxyphenylalanine studied with microdialysis. Dizdar, N., Kullman, A., Norlander, B., Olsson, J.E., Kagedal, B. Clin. Chem. (1999) [Pubmed]
  37. Microdialysis monitoring of 3,4-dihydroxyphenylalanine accumulation after decarboxylase inhibition: a means to estimate in vivo changes in tyrosine hydroxylase activity of the rat locus ceruleus. Robert, F., Lambás-Señas, L., Ortemann, C., Pujol, J.F., Renaud, B. J. Neurochem. (1993) [Pubmed]
  38. Effect of L-dopa alone and with benserazide on the spontaneous activity of striatal neurones in normal and 6-hydroxydopamine-lesioned rats. Chang, W.Y., Webster, R.A. Br. J. Pharmacol. (1997) [Pubmed]
  39. Involvement of renal dopamine synthesis in the diuretic effect of furosemide in normohydrated rats. Nowicki, S., Levin, G., Enero, M.A. J. Pharmacol. Exp. Ther. (1993) [Pubmed]
  40. Pharmacological analysis of extracellular dopamine and metabolites in the striatum of conscious as/agu rats, mutants with locomotor disorder. Campbell, J.M., Gilmore, D.P., Russell, D., Growney, C.A., Favor, G., Kennedy, A.K., Davies, R.W., Payne, A.P., Stone, T.W. Neuroscience (2000) [Pubmed]
WikiGenes - Universities